Hope for african kids with sickle cell: hydroxyurea trial expands access
NCT ID NCT06171217
First seen Apr 23, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study tests the safety and benefits of hydroxyurea, a daily medication, for children aged 3 to 10 with sickle cell anemia in Africa. The goal is to make this treatment more widely available to reduce pain and complications. Children take the drug long-term to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Monkole
Kinshasa, Democratic Republic of the Congo
-
Hospital Pediátrico David Bernardino
Luanda, Angola
-
KEMRI/Wellcome Trust Research
Kilifi, Kenya
-
Mbale Regional Hospital
Mbale, Uganda
Conditions
Explore the condition pages connected to this study.